{
    "nct_id": "NCT06147037",
    "official_title": "A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours",
    "inclusion_criteria": "Histologically and/or cytologically confirmed solid tumor that is metastatic, locally advanced, recurrent or inoperable.\n\nDisease that has progressed despite prior treatment, and for which additional effective standard therapy is not available or is contraindicated, not tolerable, or the participant refuses standard therapy.\n\nMeasurable disease as defined by RECIST Version 1.1\n\nECOG Performance status of 0 or 1\n\nAdequate organ function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Previous treatment with any systemic radiopharmaceutical\n\nPrior anti-cancer therapy unless adequate washout and recovery from toxicities\n\nContraindications to or inability to perform the imaging procedures required in this study\n\nRadiation therapy (RT) within 28 days prior to the first dose of [111In]-FPI-2107\n\nUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (â‰¥ once per month)\n\nPatients with known CNS metastatic disease unless treated and stable",
    "miscellaneous_criteria": "Key"
}